Despite a PhIII fail, Biogen pushes ALS drug tofersen forward with new analysis in move echoing Aduhelm
In a move reminiscent of its aducanumab development plans, Biogen is taking steps Friday to try to paint a failed Phase III in a positive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
